Zobrazeno 1 - 10
of 24
pro vyhledávání: '"Yuri F van der Heijden"'
Autor:
Elize Pietersen, Kim Anderson, Helen Cox, Keertan Dheda, Aihua Bian, Bryan E Shepherd, Timothy R Sterling, Robin M Warren, Yuri F van der Heijden
Publikováno v:
PLoS ONE, Vol 18, Iss 2, p e0281097 (2023)
BackgroundUpdated World Health Organization (WHO) treatment guidelines prioritize all-oral drug-resistant tuberculosis (DR-TB) regimens. Several poorly tolerated drugs, such as amikacin and para-aminosalicylic acid (PAS), remain treatment options for
Externí odkaz:
https://doaj.org/article/6aec9fada719453c84cab465a0218067
Autor:
Adoma Manful, Leslie Waller, Ben Katz, Jason Cummins, Jon Warkentin, Billy Reagon, Joanna Shaw-Kaikai, Yuwei Zhu, Yuri F. van der Heijden
Publikováno v:
BMC Infectious Diseases, Vol 20, Iss 1, Pp 1-12 (2020)
Abstract Background Treatment of tuberculosis infection (TBI) in individuals at high risk for tuberculosis (TB) disease is a priority for TB elimination in the US. Newly arrived refugees in Middle Tennessee are screened for TBI, but factors associate
Externí odkaz:
https://doaj.org/article/b5142a6a99224116be3ec471be051b49
Autor:
Lerato N. Ndlovu, Lauren Peetluk, Sashen Moodley, Shepherd Nhamoyebonde, Abigail T. Ngoepe, Matilda Mazibuko, Khadija Khan, Farina Karim, Alexander S. Pym, Fernanda Maruri, Mahomed-Yunus S. Moosa, Yuri F. van der Heijden, Timothy R. Sterling, Alasdair Leslie
Publikováno v:
Frontiers in Immunology, Vol 11 (2020)
Tuberculosis remains a leading cause of death globally despite curative treatment, partly due to the difficulty of identifying patients who will not respond to therapy. Simple host biomarkers that correlate with response to drug treatment would facil
Externí odkaz:
https://doaj.org/article/d19c89db0ce94101ac000902c11bad03
Autor:
Yuri F van der Heijden, Fernanda Maruri, Amondrea Blackman, Robert Morrison, Yan Guo, Timothy R Sterling
Publikováno v:
The Journal of Infectious Diseases.
Background We evaluated the relationship between response to efflux pump inhibition in fluoroquinolone-resistant Mycobacterium tuberculosis (Mtb) isolates and differences in gene expression and expression quantitative trait loci (eQTL). Methods We de
Autor:
Kim Anderson, Elize Pietersen, Bryan E. Shepherd, Aihua Bian, Keertan Dheda, Robin Warren, Timothy R. Sterling, Yuri F. van der Heijden
Publikováno v:
HIV medicine. 23(10)
We compared mortality between HIV-positive and HIV-negative South African adults with drug-resistant tuberculosis (DR-TB) and high incidence of acquired second-line drug resistance.We performed a retrospective review of DR-TB patients with serial sec
Autor:
Fernanda Maruri, Yan Guo, Yuri F. van der Heijden, Timothy R. Sterling, Amondrea Blackman, Peter F Rebeiro
Publikováno v:
Clin Infect Dis
Background Fluoroquinolone resistance in Mycobacterium tuberculosis (Mtb) is conferred by DNA gyrase mutations, but not all fluoroquinolone-resistant Mtb isolates have mutations detected. The optimal allele frequency threshold to identify resistance-
Publikováno v:
Open Forum Infectious Diseases. 8
Cytomegalovirus (CMV) increases tuberculosis (TB) risk, but its relationship with latent TB infection (LTBI) is unknown. Using US nationally representative data, we report that CMV was independently associated with LTBI (odds ratio, 2.94; 95% CI, 1.1
Autor:
Yan Guo, Tige R. Rustad, Bob Morrison, Yuri F. van der Heijden, Amondrea Blackman, Fernanda Maruri, Cindy Hager Nochowicz, Timothy R. Sterling, Matthew B. Scholz, David R. Sherman
Publikováno v:
J Antimicrob Chemother
Autor:
Margaretha de Vos, Serej D. Ley, Grant Theron, Yuri F. van der Heijden, Samantha Pillay, Brigitta Derendinger, Sebastien Gagneux, Frederik Sirgel, Marianna de Kock, Elizabeth M. Streicher, Robin M. Warren
Publikováno v:
Antimicrobial Agents and Chemotherapy. 65
Eis promoter mutations can confer reduced Mycobacterium tuberculosis kanamycin susceptibility. GenoType MTBDRsl, a widely used assay evaluating this region, wrongly classified 17/410 isolates as eis promoter wild type. Six out of seventeen isolates h
Autor:
Serej D, Ley, Samantha, Pillay, Elizabeth M, Streicher, Yuri F, van der Heijden, Frederik, Sirgel, Brigitta, Derendinger, Marianna, de Kock, Sébastien, Gagneux, Robin M, Warren, Grant, Theron, Margaretha, de Vos
Publikováno v:
Antimicrob Agents Chemother
Eis promoter mutations can confer reduced Mycobacterium tuberculosis kanamycin susceptibility. GenoType MTBDRsl, a widely used assay evaluating this region, wrongly classified 17/410 isolates as eis promoter wild type. Six out of seventeen isolates h